Positive Test Results Lift ViroPharma

Preliminary results from a Phase II clinical trial demonstrated that ViroPharma Inc.'s (VPHM) antiviral medication Maribavir is effective in treating the herpes infection cytomegalovirus. The stock price climbed $1.10 to close at $12.79.